Bromantane vs DNSP-11
Moderate Research vs Limited Research
compatible Both support dopaminergic function through different mechanisms. Bromantane enhances tyrosine hydroxylase gene expression while DNSP-11 provides neurotrophic support.
Molecular Data
Bromantane DNSP-11
Weight 277.18 Da ~1200 Da
Half-life ~11 hours Not well characterized
Chain — 11 amino acids
Type Adamantane-bromophenyl derivative (C16H20BrN) GDNF pro-domain derived peptide
Key Benefits
Bromantane
01 Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
02 Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
03 Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
04 Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
05 Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
06 Smooth onset and offset with no crash or rebound effects
DNSP-11
01 Protects dopaminergic neurons from neurotoxic insults
02 Stimulates dopamine production via tyrosine hydroxylase upregulation
03 Smaller molecule with improved bioavailability compared to full GDNF
04 Does not require GFRalpha1/RET receptor complex for activity
05 Preclinical evidence for neuroprotection in Parkinson's disease models
06 Compatible with intranasal and subcutaneous administration
Dosing Protocols
Bromantane
50-100 mg/day / Once daily (morning)
DNSP-11
100-200mcg per day / 1x daily (morning recommended)
General neuroprotection 100-200mcg 1x daily
Side Effects
Bromantane
Insomnia or difficulty falling asleep (if taken too late in the day)
Mild anxiety or restlessness at higher doses (above 100 mg)
Mild headache (uncommon, typically transient)
DNSP-11
Nasal irritation or mild burning sensation (intranasal route)
Injection site reactions such as redness or swelling (subcutaneous route)
Contraindications
Known hypersensitivity to bromantane or adamantane derivatives
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic impairment
Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)
Pregnancy or breastfeeding
Known peptide allergies
Very limited human safety data; use at own risk
Consult a physician before combining with dopaminergic medications
Research Evidence
Bromantane DNSP-11
Status Moderate Research Limited Research
References 5 studies 4 studies
Latest — 2014
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.